Table 2.
Ongoing trials of regorafenib combined with anti-PD-1/PD-L1 therapy.
| anti-PD-1/PD-L1 therapy | Cancer types | Clinical trials identifier | Clinical phase | Status | Primary outcome measures |
|---|---|---|---|---|---|
| Camrelizumab/Toripalimab/Pembrolizumab | HCC | NCT05048017 | II | Recruiting | PFS |
| Nivolumab | MMR Refractory CRC | NCT03712943 | I | Active, not recruiting | MTD |
| Nivolumab | HCC | NCT04170556 | I/II | Recruiting | Safety |
| Durvalumab | high-risk HCC | NCT05194293 | II | Not yet recruiting | ORR |
| Nivolumab | unresectable HCC | NCT04310709 | II | Recruiting | Response rate |
| Pembrolizumab | advanced or metastatic CRC | NCT03657641 | I/II | Recruiting | PFS, OS, DLTs |
| Nivolumab/Carelizumab/Sintilimab/Toripalimab | CRC | NCT04110093 | I/II | Recruiting | ORR, PFS |
| Carelizumab | HCC | NCT04806243 | II | Recruiting | OS |
| Nivolumab | Osteosarcoma | NCT04803877 | II | Recruiting | PFS |
| Durvalumab | advanced BTC | NCT04781192 | I/II | Recruiting | PFS, Safety |
| Pembrolizumab | advanced metastatic HCC | NCT04696055 | II | Active, not recruiting | ORR |
| Nivolumab | solid tumors | NCT04704154 | II | Recruiting | ORR |
| Pembrolizumab | HCC | NCT03347292 | I | Active, not recruiting | Safety |
HCC, hepatocellular carcinoma; CRC, colorectal cancer; BTC, biliary tract cancer; PFS, progression free survival; MTD, maximum tolerated dose; ORR, objective response rate; OS, overall survival; DLTs, dose limiting toxicity; MMR, mismatch repair.